Making access easier | Livmarli DTC Staging

Making Information Accessible for Patients and Their Families

Mirum is committed to accessibility in everything we do. We value the inclusion of everyone, with consideration of their needs and challenges, and work to ensure this is shown in the experiences we design and the websites we create. With this in mind, we continually take steps to improve LIVMARLI.com and ensure it complies with best practices and standards.

Current Accessibility Features

Accessibility and universal usability are important parts of making informed health decisions. Rooted in our mission to transform the lives of patients and their families, the Mirum team utilizes technology, advocacy, and bold action to promote the best experiences for all audiences by employing:

Industry-standard user-experience (UX) principles
Website designs with color contrast and accessibility at the forefront, according to Web Content Accessibility Guidelines (WCAG) 2
Inclusive design principles that celebrate the full scope of human diversity
Transcripts for our video content, ensuring they are accurate and complete

Our Website and Pages

Our website and landing pages are built with accessibility in mind, according to WCAG 2 best practices. The following issues are considered and remediated:

Title attributes for additional information when text is not available
Appropriate alternative text detail for images and other non-text elements
Graphics and interactive content
Form accessibility
Table accessibility
PDF and web-based brochure accessibility
Hierarchy
Line length
Font choice
Color contrast
Transcripts
Avoiding repetitive flashing in motion design

Investing in Accessibility

At Mirum, we believe it is our responsibility to ensure that content is accessible to everyone. We are dedicated to exploring new solutions, tools, and products to help enhance the overall experience. As we continue to improve our website, we will reflect those changes here within our accessibility statement and keep you informed of our efforts.

Learn More About Accessibility

The Americans with Disabilities Act (ADA) Website accessibility standards under Title II of the ADA

Federal Communications Commission (FCC) Twenty-First Century Communications and Video Accessibility Act

Web Accessibility Initiative (WAI) International standards for the web to improve accessibility for people with disabilities

Web Content Accessibility Guidelines (WCAG) 2 Checklist Compiled by Web Accessibility in Mind (Web AIM)

World Wide Web Consortium (W3C) Strategies, standards, and resources to make the web accessible to people with disabilities

We Want to Hear From You

If you encounter any accessibility issues, please let us know. We’re here to help you get the information you need.

You can reach us by visiting the Mirum Pharmaceuticals Contact Page.

Indications

LIVMARLI (maralixibat) oral solution and tablets are a prescription medicine used to treat:

cholestatic pruritus (itch) in patients who are 3 months of age and older with Alagille syndrome
cholestatic pruritus (itch) in patients who are 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
- LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein

It is not known if LIVMARLI is safe and effective in children with Alagille syndrome who are under 3 months of age. It is not known if LIVMARLI is safe and effective in children with PFIC who are under 12 months of age. It is not known if LIVMARLI is safe and effective in adults who are 65 years of age and older.

Please see full Prescribing Information, including Patient Information and Instructions for Use, for LIVMARLI.

Important Safety Information

What are the possible side effects of LIVMARLI (maralixibat) oral solution and tablets?

LIVMARLI can cause serious side effects, including:

Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but may worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your health care provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:
- nausea or vomiting
- your skin or the white part of your eye turns yellow
- dark or brown urine
- pain on the right side of your stomach (abdomen)
- fullness, bloating, or fluid in your stomach area (ascites)
- loss of appetite
- bleeding or bruising more easily than normal, including vomiting blood
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Diarrhea can also cause the loss of too much body fluid (severe dehydration). Your health care provider may advise you to monitor for new or worsening stomach problems, including stomach pain, diarrhea, blood in your stool, or vomiting
Tell your health care provider right away if you have any new or worsening signs or symptoms of stomach and intestinal problems, including:
- diarrhea
- more frequent bowel movements than usual
- stools that are black, tarry, or sticky, or have blood or mucous
- severe stomach-area pain or tenderness
- vomiting
- urinating less often than usual
- dizziness
- headache
A condition called Fat-Soluble Vitamin (FSV) Deficiency, caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat, is common in patients with Alagille syndrome and PFIC, but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment, and may monitor for bone fractures and bleeding, which are common side effects

Tell your health care provider about all medicines that you take, as LIVMARLI may interact with other medicines. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take LIVMARLI at least 4 hours before or 4 hours after you take that medicine.

Your health care provider may change your dose, or temporarily or permanently stop treatment if you have certain side effects.

LIVMARLI is available in oral solution and tablet formulations. In patients with Alagille syndrome, LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. In patients with PFIC, LIVMARLI is taken by mouth, 2 times each day, 30 minutes before a meal. For the oral solution, be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information and Instructions for Use, for LIVMARLI.